Rutgers University announced on Monday that the US Food and Drug Administration (FDA) has granted emergency use authorization (EUA) to Rutgers RUCDR Infinite Biologics and its collaborators for a new saliva-based COVID-19 test.
Andrew Brooks, chief operating officer and director of technology development at RUCDR, believes that the new method will allow for broader population screening than the current method of nose and throat swabs and will act as a safer alternative.
